Some Wall Street analysts have questioned orforglipron’s sales outlook in obesity, but see great potential in diabetes, where ...
The German biotech banked one of the larger funding rounds this year to support an ovarian and non-small cell lung cancer ...
Among the largest private biotech funding rounds this year, the financing will support global trials of an obesity shot that ...
AstraZeneca followed the blueprint of a deal Pfizer recently cut with the White House. Elsewhere, issues at a Novo plant are ...
A deal valuing the Boston biotech’s stock at $700 million hands BioCryst a long-acting injectable for hereditary angioedema ...
However, if pharma manufacturers aren’t using RWD in a strategic way, they’ll miss out on its full potential. And with that, ...
CEO Joaquin Duato said the spinout will help the healthcare giant focus on medtech areas with higher growth and margins, such ...
Bringing in a recruitment partner early gives sponsors the chance to test their protocols with real patients and gather ...
A settlement could extend the exclusivity of the world’s best-selling HIV medicine to 2036. Elsewhere, an AstraZeneca drug ...
Living with an autoimmune disease often means navigating a lifelong, complex condition. A recent study estimates that ...
Excellergy is developing medicines that combat allergic responses in three different ways, a multipronged effect the company ...
Early packaging decisions can make or break your drug's market launch. Choose the best packaging and secure the future.
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback